This study has demonstrated the role of the novel fusion gene PLEKHA1-TACC2 in VM formation and its potential as a biomarker for effective ESCC treatment, but it nonetheless has certain limitations. Here, TACC2 is linked to esophageal squamous cell carcinoma.